1053 related articles for article (PubMed ID: 27447711)
21. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Kashima J; Okuma Y; Miwa M; Hosomi Y
Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
[TBL] [Abstract][Full Text] [Related]
22. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
Song Z; Zhang Y
J Clin Neurosci; 2014 Apr; 21(4):591-5. PubMed ID: 24256883
[TBL] [Abstract][Full Text] [Related]
23. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
Lee JY; Lim SH; Kim M; Kim S; Jung HA; Chang WJ; Choi MK; Hong JY; Lee SJ; Sun JM; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2014 May; 73(5):1063-70. PubMed ID: 24663503
[TBL] [Abstract][Full Text] [Related]
24. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors.
Lee JH; Chen HY; Hsu FM; Chen JS; Liao WY; Shih JY; Yu CJ; Chen KY; Tsai TH; Yang JC
Oncologist; 2019 Dec; 24(12):e1417-e1425. PubMed ID: 31127020
[TBL] [Abstract][Full Text] [Related]
25. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
[TBL] [Abstract][Full Text] [Related]
26. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.
Imai H; Shukuya T; Takahashi T; Fujiwara S; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Kaira K; Murakami H; Harada H; Endo M; Nakajima T; Yamamoto N
Anticancer Res; 2013 Aug; 33(8):3279-84. PubMed ID: 23898092
[TBL] [Abstract][Full Text] [Related]
29. Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
Zhou L; He J; Xiong W; Liu Y; Xiang J; Yu Q; Liang M; Zhou X; Ding Z; Huang M; Ren L; Zhu J; Li L; Hou M; Ding L; Tan F; Lu Y
Lung Cancer; 2016 Jun; 96():93-100. PubMed ID: 27133757
[TBL] [Abstract][Full Text] [Related]
30. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
[TBL] [Abstract][Full Text] [Related]
31. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Yu X; Sheng J; Pan G; Fan Y
Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases.
Saida Y; Watanabe S; Abe T; Shoji S; Nozaki K; Ichikawa K; Kondo R; Koyama K; Miura S; Tanaka H; Okajima M; Terada M; Ishida T; Tsukada H; Makino M; Iwashima A; Sato K; Matsumoto N; Yoshizawa H; Kikuchi T
Thorac Cancer; 2019 Nov; 10(11):2106-2116. PubMed ID: 31507098
[TBL] [Abstract][Full Text] [Related]
33. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
34. Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.
Takeuchi A; Oguri T; Sone K; Ito K; Kitamura Y; Inoue Y; Asano T; Fukuda S; Kanemitsu Y; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
Anticancer Res; 2017 Oct; 37(10):5771-5776. PubMed ID: 28982900
[TBL] [Abstract][Full Text] [Related]
35. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
Johung KL; Yeh N; Desai NB; Williams TM; Lautenschlaeger T; Arvold ND; Ning MS; Attia A; Lovly CM; Goldberg S; Beal K; Yu JB; Kavanagh BD; Chiang VL; Camidge DR; Contessa JN
J Clin Oncol; 2016 Jan; 34(2):123-9. PubMed ID: 26438117
[TBL] [Abstract][Full Text] [Related]
36. A review of whole brain radiotherapy outcomes in a high epidermal growth factor receptor mutation rate population: Does QUARTZ apply in Asia?
Ng IW; Tey JCS; Chia DWT; Yee CM; Cheo TST
Asia Pac J Clin Oncol; 2019 Dec; 15(6):353-357. PubMed ID: 31267659
[TBL] [Abstract][Full Text] [Related]
37. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
Cai L; Zhu JF; Zhang XW; Lin SX; Su XD; Lin P; Chen K; Zhang LJ
J Neurooncol; 2014 Nov; 120(2):423-30. PubMed ID: 25098700
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.
Yang WC; Xiao F; Shih JY; Ho CC; Chen YF; Tseng HM; Chen KY; Liao WY; Yu CJ; Yang JC; Kuo SH; Cheng JC; Yang PC; Hsu FM
Radiother Oncol; 2018 Feb; 126(2):368-374. PubMed ID: 29111173
[TBL] [Abstract][Full Text] [Related]
39. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure.
Shukuya T; Takahashi T; Naito T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Murakami H; Harada H; Mitsuya K; Endo M; Nakasu Y; Takahashi K; Yamamoto N
Lung Cancer; 2011 Dec; 74(3):457-61. PubMed ID: 21571388
[TBL] [Abstract][Full Text] [Related]
40. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]